Zentalis Pharmaceuticals (ZNTL) Appoints Jan Skvarka to its Board

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. MRK
8. LVS
9. CSX
10. LRCX

Go back to Zentalis Pharmaceuticals (ZNTL) Appoints Jan Skvarka to its Board

Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors

September 12, 2022 7:00 AM EDT

NEW YORK and SAN DIEGO, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Jan Skvarka, PhD, MBA to its Board of Directors. Dr. Skvarka is an accomplished biopharmaceutical executive bringing over three decades of extensive operational, strategic and financial expertise to Zentalis.

We are excited to welcome Jan, an experienced life sciences leader, to our Board of Directors, said Dr. Kimberly Blackwell, Chief Executive Officer of... More